2023-10-30 16:00Financial Performance - The company's operating revenue for Q3 2023 was ¥9,304,926,476.24, a decrease of 9.44% compared to ¥10,270,017,624.77 in the same period last year[5] - Net profit attributable to shareholders for Q3 2023 was ¥505,594,060.92, down 43.85% from ¥907,033,448.21 year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥101,288,692.64, a significant decline of 89.84% compared to ¥997,232,651.37 in the previous year[5] - The net cash flow from operating activities for Q3 2023 was ¥651,632,352.02, a decrease of 51.55% from ¥1,353,331,940.11 in the same period last year[5] - Basic earnings per share for Q3 2023 were ¥0.19, down 44.12% from ¥0.34 in the same period last year[6] - The weighted average return on net assets was 1.11%, a decrease of 1.07 percentage points compared to 2.18% in the previous year[6] - Total operating revenue for the first three quarters of 2023 was ¥30,700,119,056.12, a decrease of 2.9% from ¥31,622,769,575.50 in the same period of 2022[25] - Net profit attributable to shareholders of the parent company for the first three quarters of 2023 was ¥2,283,065,930.63, down from ¥2,436,199,195.90 in the same period of 2022, representing a decline of 6.3%[26] - The total comprehensive income for the first three quarters of 2023 was ¥3,036,856,754.24, down from ¥3,209,936,501.01 in the same period of 2022, a decline of 5.4%[26] Impairment and Expenses - The company recognized impairment losses of approximately ¥510 million on COVID-related products due to a significant decrease in market demand[7] - The decline in revenue from pandemic-related products was accompanied by increased management and financial expenses[8] - The net profit attributable to shareholders decreased by 43.85% due to significant impairment losses related to COVID-19 products, totaling approximately 510 million RMB, and increased management and financial expenses[10] - The financial expenses for the first three quarters of 2023 were CNY 427,664,445, up from CNY 300,817,176 in the previous year, reflecting an increase of approximately 42.2%[32] Research and Development - The company's R&D investment totaled CNY 4.291 billion, representing a year-on-year increase of 13.67%, with R&D expenses amounting to CNY 3.155 billion, up 10.22%[15] - Research and development expenses increased to ¥3,155,101,729.15 in the first three quarters of 2023, compared to ¥2,862,643,999.21 in the same period of 2022, reflecting a growth of 10.2%[25] - The company received approval for its first innovative drug, Hanshu (Sruvulimab injection), for four indications, including esophageal squamous cell carcinoma (ESCC)[15] Assets and Liabilities - The total assets at the end of Q3 2023 were ¥110,767,244,296.81, an increase of 3.36% from ¥107,163,907,232.34 at the end of the previous year[6] - The total liabilities as of the end of Q3 2023 amounted to ¥54,784,884,542.16, an increase of 3.3% from ¥53,054,997,618.99 at the end of Q3 2022[24] - The company's total equity reached ¥55,982,359,754.65 at the end of Q3 2023, up from ¥54,108,909,613.35 in Q3 2022, indicating a growth of 3.5%[24] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 305,081[12] - The largest shareholder, Fosun High Technology, held 886,315,955 shares, representing 33.16% of the total shares[12] Cash Flow - The net cash flow from operating activities decreased by 51.55%, primarily due to changes in operating income and profit[10] - The net cash flow from operating activities for the first three quarters of 2023 was approximately ¥2.46 billion, a decrease of 21.7% compared to ¥3.14 billion in the same period of 2022[28] - Total cash inflow from investment activities was approximately ¥3.13 billion, down from ¥3.91 billion year-over-year, resulting in a net cash flow from investment activities of approximately -¥3.28 billion[28] - Cash inflow from financing activities decreased to approximately ¥18.44 billion from ¥29.88 billion in the previous year, leading to a net cash flow from financing activities of approximately -¥0.40 billion[29] Strategic Developments - The company made significant progress in the localization of medical devices, with the first domestically produced Da Vinci Xi surgical robot officially launched in October 2023[18] - The company expanded its collaboration with KGbio to include 12 additional countries in the Middle East and North Africa for the commercialization of Sruvulimab injection[19] - The controlling shareholder plans to increase its stake in the company by no less than CNY 100 million over the next 12 months, having already acquired 720,000 shares for approximately CNY 20.08 million[20] - The company adjusted its fundraising project allocations to accelerate the development of innovative drugs, reallocating CNY 193.14 million from one project to another related to clinical trials and product launches[21]